Comparative Pharmacology
Head-to-head clinical analysis: IMKELDI versus POLIVY.
Peer-Reviewed Evidence
Head-to-head clinical analysis: IMKELDI versus POLIVY.
IMKELDI vs POLIVY
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Imkelde (imipenem/cilastatin/relebactam) is a combination antibacterial agent. Imipenem inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs). Cilastatin inhibits renal dehydropeptidase I, preventing renal metabolism of imipenem. Relebactam is a beta-lactamase inhibitor that protects imipenem from degradation by certain serine beta-lactamases, including KPC and some AmpC enzymes.
Polivy is an antibody-drug conjugate (ADC) composed of a CD79b-directed monoclonal antibody (polatuzumab vedotin) conjugated to the microtubule-disrupting agent monomethyl auristatin E (MMAE). Upon binding to CD79b on B-cells, the ADC is internalized and MMAE is released via proteolytic cleavage, leading to cell cycle arrest and apoptosis.
10 mg orally once daily
1.8 mg/kg intravenously every 21 days in combination with bendamustine and rituximab for up to 6 cycles.
None Documented
None Documented
Terminal elimination half-life: 12 hours (range 10-14 hours) in healthy adults; extended to 24-30 hours in moderate renal impairment (CrCl 30-50 mL/min). Clinical context: Steady state achieved after 3-4 days. Twice-daily dosing maintains therapeutic levels.
The terminal elimination half-life of polatuzumab vedotin is approximately 12 days (range 8–20 days) for the antibody-drug conjugate. This supports a dosing interval of every 3 weeks. The half-life may be prolonged in patients with severe hepatic impairment.
Primarily renal excretion of unchanged drug and metabolites; 70% recovered in urine (60% unchanged, 10% as glucuronide conjugate) and 30% in feces (mainly metabolites) over 72 hours.
Polivy (polatuzumab vedotin) is eliminated primarily through catabolism into small peptides and amino acids. The antibody-drug conjugate is not significantly excreted renally as intact compound; approximately <1% of the dose is excreted unchanged in urine. The majority of the drug is metabolized and eliminated via biliary/fecal routes, with approximately 80% of the total dose recovered in feces over 3 weeks, primarily as metabolites.
Category C
Category C
Antineoplastic Agent
Antineoplastic Agent